For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a genuine change. These novel therapies protect the transthyretin protein, halting its harmful build-up and lessening the severity